RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $1.95 billion. The enterprise value is $1.88 billion.
| Market Cap | 1.95B |
| Enterprise Value | 1.88B |
Important Dates
The next confirmed earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 36.99 million shares outstanding. The number of shares has increased by 24.56% in one year.
| Shares Outstanding | 36.99M |
| Shares Change (YoY) | +24.56% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 12.99% |
| Owned by Institutions (%) | 90.66% |
| Float | 27.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 144.93 |
| PS Ratio | 22.46 |
| Forward PS | 14.92 |
| PB Ratio | 12.48 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.06, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.06 |
| Quick Ratio | 7.09 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.69 |
Financial Efficiency
Return on equity (ROE) is -31.20% and return on invested capital (ROIC) is -30.66%.
| Return on Equity (ROE) | -31.20% |
| Return on Assets (ROA) | -25.50% |
| Return on Capital (ROIC) | -30.66% |
| Revenue Per Employee | $238,174 |
| Profits Per Employee | -$129,968 |
| Employee Count | 374 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.19 |
Taxes
In the past 12 months, RxSight has paid $20,000 in taxes.
| Income Tax | 20,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +200.74% in the last 52 weeks. The beta is 1.22, so RxSight's price volatility has been higher than the market average.
| Beta (1Y) | 1.22 |
| 52-Week Price Change | +200.74% |
| 50-Day Moving Average | 52.59 |
| 200-Day Moving Average | 37.65 |
| Relative Strength Index (RSI) | 50.93 |
| Average Volume (30 Days) | 401,125 |
Short Selling Information
The latest short interest is 1.29 million, so 3.49% of the outstanding shares have been sold short.
| Short Interest | 1.29M |
| Short Previous Month | 1.30M |
| Short % of Shares Out | 3.49% |
| Short % of Float | 4.64% |
| Short Ratio (days to cover) | 2.88 |
Income Statement
In the last 12 months, RxSight had revenue of $89.08 million and -$48.61 million in losses. Loss per share was -$1.41.
| Revenue | 89.08M |
| Gross Profit | 53.77M |
| Operating Income | -50.09M |
| Pretax Income | -48.59M |
| Net Income | -48.61M |
| EBITDA | -41.04M |
| EBIT | -45.28M |
| Loss Per Share | -$1.41 |
Balance Sheet
The company has $127.89 million in cash and $3.01 million in debt, giving a net cash position of $124.88 million or $3.38 per share.
| Cash & Cash Equivalents | 127.89M |
| Total Debt | 3.01M |
| Net Cash | 124.88M |
| Net Cash Per Share | $3.38 |
| Equity / Book Value | 160.36M |
| Book Value Per Share | 4.34 |
| Working Capital | 147.50M |
Cash Flow
In the last 12 months, operating cash flow was -$41.59 million and capital expenditures -$4.81 million, giving a free cash flow of -$46.41 million.
| Operating Cash Flow | -41.59M |
| Capital Expenditures | -4.81M |
| Free Cash Flow | -46.41M |
| FCF Per Share | -$1.35 |
Margins
Gross margin is 60.36%, with operating and profit margins of -56.23% and -54.57%.
| Gross Margin | 60.36% |
| Operating Margin | -56.23% |
| Pretax Margin | -54.55% |
| Profit Margin | -54.57% |
| EBITDA Margin | -46.07% |
| EBIT Margin | -50.83% |
| FCF Margin | -52.10% |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.56% |
| Shareholder Yield | -24.56% |
| Earnings Yield | -2.43% |
| FCF Yield | -2.32% |
Analyst Forecast
The average price target for RxSight is $51.14, which is -3.22% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.14 |
| Price Target Difference | -3.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 50.19 and a Piotroski F-Score of 5.
| Altman Z-Score | 50.19 |
| Piotroski F-Score | 5 |